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Methicillin-resistant Staphylococcus aureus (MRSA) has become a leading cause of
colonization and infection in both acute and chronic soft-tissue wounds. Objective:
Our objective is to define this current epidemic problem caused by both community-
acquired MRSA (CA-MRSA) and hospital-acquired MRSA (HA-MRSA), focusing on
the similarities and differences between these 2 isolates as well as the impact on wound
managementdecisions.Methods:Methodsusedincludealiteraturereviewonthegrowth
of the current MRSA problem and its International scope. In addition, a current up-to-
date assessment had been made of the problem and the current approach to management
of MRSA in acute soft-tissue and chronic wounds. Burns are not discussed because this
injury usually does not fit either categories and is managed quite uniquely. Results:
Results included the following: (1) There are very distinct properties of CA-MRSA and
HA-MRSA, which must be considered for acute and chronic wound care. Management
of both requires rigorous barrier precaution techniques to avoid cross-contamination.
The presence of MRSA as a carrier state increases the risk of both a systemic and local
wound infection in the carrier. There are large and increasing reservoirs of CA-MRSA
and HA-MRSA worldwide leading to more bacteremias and wound problems. Topical
antimicrobial therapy has not been addressed in managing MRSA in acute and chronic
wounds.Conclusion:ConclusionsincludethefactthatbothHA-MRSAandCA-MRSA
woundinfectionsarerapidlyincreasing,especiallywithCA-MRSA.Thishighincidence
requires appropriate wound prediction and management decisions as well as attempts to
avoid further cross-contamination and reservoir growth. Topical antimicrobial therapy
would seem to be an important component in controlling this tremendous problem. Yet
this topic has yet to be adequately addressed.
The methicillin-resistant Staphylococcus aureus (MRSA) bacterium was recognized
as an important clinical pathogen in the 1960s where it was found exclusively in a hospital
setting.1,2
As recently as 20 years ago, MRSA was still considered to be a hospital-acquired
pathogen. The usual infection was a bacteremia in a compromised patient on antibiotics
after a prolonged hospital stay.
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Today,MRSAistheleadingcauseofanosocomialinfectioninmostpartsoftheworld.
Also, MRSA is now the most identifiable cause of acute skin and soft-tissue infections seen
in the urban emergency department setting.3–6
Overarelativelyshort-timeperiod,MRSAhasalsoevolvedinto2quitedifferenttypes,
each with different effects on wound epidemiology, and wound care strategy.
The initial variant of MRSA is now called health- or hospital-acquired methicillin
resistant Staphylococcus aureus (HA-MRSA), as that is where the reservoir in large part
resides.
AnewerandveryrapidlyspreadingtypeofMRSAhasrecentlyevolvedinacommunity
setting and in a healthy population and is referred to as community-acquired methicillin-
resistant Staphylococcus aureus (CA-MRSA).
The CA-MRSA has been spreading at an epidemic rate and has now become a major
cause of acute wound infection. The HA-MRSA is the type most likely to be seen in major
burns. Both types of MRSA are seen in chronic wounds.
MRSAhasbecomeahugeworldwidehealththreatandanupdateonitscurrentimpact
on wounds is warranted. The specific characteristics of HA-MRSA and CA-MRSA are
presented, as well as, the impact these organisms have on acute and chronic wounds.3–6
OVERVIEW OF HOSPITAL-ACQUIRED HA-MRSA
AND CA-MRSA INFECTION
The first reports of MRSA infection occurred in the 1960s, felt to be from a widely dissem-
inated “Iberian clone,” which was first seen in Europe.1,2 Clinical reports were confined to
thehospitalsetting.TheriskfactorsforanMRSAinfectionwerenotedtobethosedescribed
in Table 1. The risk factors were confinement in a hospital unit, with high-risk patients, use
of multiple antibiotics, and common use of intravenous catheters.
A number of epidemics were reported beginning in the 1970s, in various high-risk
hospital settings (Table 2), with the major types of infections being bacteremias followed
by pneumonias, and then wound infections.7–10
To date, bacteremias continue to be a much more common nosocomial infection prob-
lem with HA-MRSA.2,11,12 Recently, there has been a marked increase in the prevalence
of MRSA throughout the world, especially in the past decade.13–18 The MRSA infections
Table 1. Risk factors for HA-MRSA∗
Long hospital presence in ICU/burn/NICU
Prior or present history of antibiotic use
In-dwelling intravenous catheter
Previous history of MRSA
Immune impaired or compromised Host
Open wounds
∗HA-MRSA indicates health-acquired hospital-acquired
methicillin resistant Staphylococcus aureus; ICU, intensive
care unit; NICU, neonatal intensive care unit; and MRSA,
methicillin-resistant Staphylococcus aureus.
87JOURNAL OF BURNS AND WOUNDS VOLUME 7
Table 2. Common populations for HA-MRSA
epidemics and the common infection site∗
Burn centers Neonatal units/NICU
Bacteremia Bacteremia
Wounds Lungs
Lungs Renal dialysis centers
Bone marrow transplant Bacteremia
Bacteremia Long-term care
Lungs Pneumonia
Wounds Chronic wounds
ICU medical/surgical
Bacteremia
Lungs
Wounds
∗HA-MRSA indicates health environment or hospital acquired;
NICU, neonatal intensive care unit; and ICU, intensive care unit.
are tracked through causes of a bacteremia,13–19 most of which could be considered HA-
MRSA due to the presence of risk factors.
Interestingly, the incidence of MRSA bacteremias varies dramatically throughout the
world with only 0.5% of total cases of bacteremia reported in Iceland being MRSA, while
44% of the reported cases in Greece were caused by MRSA. There was an overall increase,
in MRSA bacteremias, in Europe of 20%, between 1999 and 2002, with the increase in
Germany and Italy being 50%.15–24 In Korea, more than 70% of nosocomial infection cases
are caused by MRSA.19 The specific types of MRSA have been monitored carefully in the
United States and Europe.
Aroundtheyear1995,anewformofMRSAbecameevident,whichwasfoundoutside
the Health System.23–28 This organism, which apparently evolved from a different strain
of MRSA than the hospital acquired was first identified in communities such as long-term
care facilities. This Staphylococcus aureus named CA-MRSA has actually been defined on
the basis of its differences from the health-acquired strain.
The clinical characteristics typically include no recent hospitalization or surgery, no
antibiotics, no residence in a long-term care facility, no presence of any invasive medical
devices, or no known infection with HA-MRSA (Table 3). To date, CA-MRSA infections
tendtobedisproportionatelyfoundinhealthychildrenandyoungadults,sportsparticipants,
military recruits, and people with a lower socioeconomic status. Frequent skin-to-skin
contact and hygiene problems are also common factors seen.
As opposed to bacteremia, typically seen with HA-MRSA, soft-tissue infections are
very commonly caused by CA-MRSA.29–30
A number of microbiological differences have also been noted (Table 4).29–31
The CA-MRSA bacterium is more sensitive to antibiotics, with most isolates being
sensitive to TMP/SMX, tetracycline, clindamycin, vancomycin, and linezolid.28–32 In ad-
dition, the USA 300 isolate appears to be the most common organism found in the United
States. Also, the SCC mec type IV and the PVL are usually present, which are typically
not found in HA-MRSA. The role of the PVL is not yet clear but it is known to correspond
with tissue necrosis, a major feature seen in the soft-tissue infections.28–32
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Table 3. Clinical proﬁle with CA-MRSA infections∗,†
Commonly seen in healthy children, young adults
Sports, military recruits, skin-to-skin contact
Low socioeconomic status
Hygiene problems
No criteria suggestive of HA-MRSA
Primary infection of skin and soft tissues
Abscess formation
∗Not seen with HA-MRSA.
†CA-MRSA indicates community-acquired methicillin-resistant
Staphylococcus aureus; HA-MRSA, hospital-acquired Methicillin-
resistant Staphylococcus aureus.
It appears that epidemiological efforts in the United State has clearly been focused
on separating the 2 MRSA populations and their carrier states while on other parts of the
world, the 2 populations are not separated (Fig 1).15–24
LikeHA-MRSA,thespreadoftheCA-MRSA,innosocomialinfections,hasbeenwell
recognized to be that of person-to-person contact. The only effective means of avoiding
cross-containment has been very aggressive isolation techniques and improved hygiene,
especially hand-washing vigilance.4
Surveillance cultures of hospitalized patients and care providers, with positive cul-
tures, has been the common approach used to control the hospital problem. More recently,
prophylactic treatment of all care providers and patients, in high-risk hospital units, has
been shown to decrease MRSA infection in select series.28–30 A more aggressive approach
known as “search and destroy” has been implemented in facilities in Europe, with high
MRSA infection rates, using the rapid screening RDT testing, where positive patients and
staff are treated.31 In the United States, intensive personnel screening has been shown to be
effective but has not been implemented as Standard of Care. Topical intranasal Mupirocin
cream is the most commonly used treatment for MRSA nasal colonization.1,34
Despite increasing vigilance, the prevalence of both forms of MRSA continues to
increase. A MRSA carrier state has long been recognized in the healthcare system and is
nowmuchmoreevidentinthecommunity.Thenaresremainsthemostcommonsitefollowed
by the skin for HA-MRSA, while skin is the more common carrier site for CA-MRSA.34–38
Of importance with CA-MRSA is that the asymptomatic carrier also frequently develops
an acute skin or a soft-tissue infection,34–38 while the hospital worker carrying HA-MRSA
in the nares seldom becomes infected with the organism
Asof2001,theCentersforDiseaseControlandPrevention(CDC)estimatedthatthere
wereanestimated2millionMRSAcarriersintheUnitedStatesalone.28–30 Thisnumberhas
Table 4. Microbiological properties of CA-
MRSA not seen with HA-MRSA
Antimicrobial sensitivity
Presence of SCC mec type gene
Presence of Panton-Valentine leukocidin toxin gene
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Figure 1. Evolution of MRSA and nosocomial infection from 1960 to
present. From CDC research.
certainly increased since that time. Most of the MRSA carriers are now in the community,
as opposed to 20 years ago when the hospital worker was the major reservoir.
ControlofCA-MRSAhasfocusedonhygieneeducationandavoidingthedevelopment
of MRSA reservoirs, for example, in outpatient type facilities, through screening and pre-
vention campaigns. Certainly prevention of the spread of MRSA from a known carrier, by
properbarriercontrolsandeducation,isessential.Prophylacticuseofmupirocinointmentin
long-termcarefacilitieshasshownadecreaseininfections.Howeverthereremainsconcern
over the development of resistance. There was actually evidence of increasing mupirocin
resistance beginning back in the 1970s with over usage.38–40 Alternative preventive mea-
sures and treatments will need to be developed, probably using silver products, which are
known to kill MRSA.4(M2)
ACUTE SKIN AND SOFT-TISSUE INFECTION CAUSED BY MRSA
EXCLUDING BURNS
The focus of this discussion is the management of typical traumatic soft-tissue wounds
and/ordermatosisthatbecomesinfected,withMRSA,andrequireslocalwoundcare.These
wounds are typically not exposed to the risk factors for HA-MRSA. Burn injury is a very
distinct wound and will be described separately.
Staphylococcus aureus has always been a major source of infection in acute soft-tissue
wounds, but MRSA has only been an infecting organism in a small fraction of the total.
However, CA-MRSA has now rapidly become both a virulent, and extremely common
wound pathogen.42–49
Currently, CA-MRSA is reported to be the most identifiable cause of acute skin and
soft-tissue infections in urban emergency departments in the United States, with the inci-
dence doubling in the last 3 to 4 years (Fig 2). In addition, the bacterial isolate involved is
quite specific, with 97% of strains being the USA 300 type, and the majority also having
the PVL. This gene may explain the typical tissue necrosis and abscess formation seen with
this form of infection.
In general, infections caused by methicillin sensitive Staphylococcus aureus and me-
thicillin resistant Staphylococcus aureus are quite similar. However, CA-MRSA tends to
produce more abscess formation and tissue necrosis.
One common and quite interesting presentation of a CA-MRSA infection is that of
a small painful skin pustule with surrounding cellulitis, often described as a “spider bite”
which then rapidly evolves into an abscess with progressive cellulitis (Figs. 3 and 4).
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Figure 2. The percentage of total of acute soft tissue wounds, infected with MRSA, is
shown over time for 4 recent emergency department based clinical studies.21,32,43,44
The clinical profile of CA-MRSA infection is described in Table 3. More severe in-
fections such as necrotizing fascitis are also seen especially in children and young adults,
who tend to have the more severe soft-tissue infections with this organism.
The majority of patients, in the most recent multi center studies with acute skin and
soft-tissue infections, were treated with a prophylactic B-lactam antibiotics not effective
against CA-MRSA.43–44 Lack of effectiveness was detected later with the return of routine
cultureresults.Interestingly,themajorityofpatientswhohadabscesses,whichwereinitially
drained,improvedevenwithineffectiveantibiotics,indicatingtheimportanceofaggressive
localwoundcare.Onlypatientswithinadequatedrainageorsignificantcellulitisprogressed
before changing the antibiotic regime. 43,44
Figure 3. Necrotic, draining wound infected by
CA-MRSA(“Spider Bite”). Note the purulent na-
ture of the small wound with surrounding cellulitis.
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Figure 4. Necrotic pustule infected with CA-
MRSA. Note the necrotizing property in the wound
with surrounding cellulitis.
More recently, a rapid screening test RDT for MRS A has become available in most
major centers. This technique uses a quick multiplex immunocapture-coupled PCR and
only takes a few hours.
Because of the rapid increase in CA-MRSA acute infections, the CDC recently pub-
lishednewGuidelinesfortheManagementofAcuteSkinandSoftTissueInfections(Table5).
There are a number of highlighted approaches for acute wound management.
FirstofallCA-MRSAislikelytobethecauseofanacutepurulentsofttissueinfection
of the skin. Second, cultures should be obtained not only for specific patient wound-care
decisions, but to develop a regional profile for this increasing pathogen. At present, there
is not sufficient information available to recommend the need for specific typing and char-
acterization of the MRSA. However, at some point in time, a genetic profile may be quite
valuable in tracking a current cluster. Third, it appears that the CA-MRSA causes local
tissue necrosis and aggressive unroofing of the wound leads to optimum results.
Fourth,empiricantibioticsareselectedonthebasisofevidenceoflocalwoundinvasion
with systemic symptoms. However, if there is a high regional incidence of CA-MRSA or
Table 5. CDC guidelines for management of acute SSTIs∗
1. Consider CA-MRSA a likely cause of acute SSTIs
including purulent “Spider Bites”
4. Utilize Empiric Antibiotic Therapy based on
wound indications, considering CA-MRSA
coverage based on risk factors
2. Obtain wound cultures and sensitivity For
individual patient purposes To determine local
CA-MRSA characteristics
5. Maintain Standard Infection Control Precautions
in the Treatment area. MRSA can be readily
transmitted in the health care environment
3. Utilize aggressive incision and drainage
approaches to the wound, followed by standard
wound management practices†
6. Patient Infection Control Education is important
to avoid the spread of CA-MRSA back into the
community
∗CDC indicates Centers for Disease Control and Prevention; SSTIs, skin and soft-tissue infections; and CA-MRSA,
community-acquired methicillin-resistant Staphylococcus aureus.
†Currently there are no good data as to the ideal topical antimicrobial therapy for MRSA skin and soft tissue infections.
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Table 6. Antimicrobialtherapyforsuspectedcommunity-acquired
methicillin-resistant Staphylococcus aureus wound infection∗
Suspected infection: Doxycycline, bacterium, tetracyline, clindamycin†
Serious infection/bacteria:Vancomycin or linezolid48,49
Topical antibiotic: mupirocin, silver products51,52
∗The standard management of a typical hospital-acquired methicillin-resistant
Staphylococcus aureus infection would be Linezolid or Vancomycin.
† Clindamycin resistance is an increasing problem.
risk factors for this infection are increased, appropriate CA-MRSA antibiotics should be
selected (Table 6).
Community acquired MRSA is quite antibiotic sensitive.
Fifth, as previously mentioned, the acute care setting needs to follow rigorous in-
fection control precautions, to avoid healthcare worker and environment colonization and
subsequent increased risk of cross-contamination.
A point of controversy may be the approach to the carrier states in personnel and
patients. The typical carrier sites are the nares and the skin. It is well known that a
carrier state can lead to both a soft tissue infection in the same patient and to cross-
contamination.35,37–45At present, there is insufficient data for acute wound care facilities,
to recommend prophylactic decolonization of the healthcare staff and patients.
Finally,patienteducationbecomesakeyfactorinmanagementtoavoidspreadingCA-
MRSA to an entire household, chronic care facility, sports team, or any other contacts of
the patient.
Of major interest is the apparent lack of attention given to the approach of local wound
care for the acute MRSA-infected wound. It would seem logical that a rapid local control of
the organism using a tested appropriate topical antimicrobial agent would decrease wound
bacterial load and also diminish the potential for cross-contamination. Local wound care
management, in the literature reviewed, appears to be at the discretion of the healthcare
provider. This approach is very different from that used in the management of burns where
topical agents are considered standard of care.
Burns will not be discussed in this review because although most burns are acute soft-
tissuewounds,usuallyalloftheliteraturefocusesonmajorburnsinburncenters.Therefore,
theimpactofMRSAisonlyavailableforaverysmallportionofthesewoundsandthemajor
problems are not related to the wounds but rather bacteremias and lung infections.
CHRONIC WOUNDS AND MRSA
There is now a well-recognized increase in MRSA colonization and infection in chronic
wounds.52–57 The increase appears to be comparable to the worldwide increase in MRSA
in acute wounds.
TheMRSApresentstwoproblems,thefirstrelatestothechronicwoundbeingasource
of other MRSA nosocomial infections and the second relates to the impact of MRSA on
the chronic wound itself.
It has been well demonstrated that patients admitted for an acute injury or illness, who
have chronic wounds growing MRSA, have an increased risk of a bacteremia with MRSA
being the organism.57
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As previously described, the mortality of a, MRSA bacteremia is significantly higher
than a methicillin-sensitive Staphylococcus aureus.77 The increasing reservoir of MRSA in
the chronic wound population becomes a source of other nosocomial infections.58,59 The
chronicity of the chronic wound also increase the risk of cross-contamination.
The best data on the effect of MRSA on the wound itself are in the diabetic ulcer
population.58–60 Staphylococcus aureus appears to be the most common pathogen, among
the gram-positive bacteria, isolated from the diabetic ulcer. Several recent reports have
indicated an incidence of MRSA growth of up to 50% in these ulcers and the MRSA
ulcers are more likely to become infected.59–62 Suggesting increased virulence, CA-MRSA
appears to be more virulent in a wound than HA-MRSA.
Infection in these studies was diagnosed according to the criteria proposed by the
International Consensus on the Diabetic Foot.60 Interestingly, several studies have reported
that there appears to be no difference in diabetic ulcer healing rate when colonized by
MSSA,methicillin-susceptibleStaphylococcusauerus,orMRSA.58–61Ofcourse,itismuch
more difficult to treat a multi-drug-resistant MRSA with systemic antibiotics that must be
considered when discussing morbidity.60
Other studies have reported an increase in hospital stay, increased cost, and increased
morbidity and mortality with an MRSA foot infection compared to other diabetic foot ulcer
infections.62–64
Interestingly, many of these studies have indicated that the typical risk factors for
the development of HA-MRSA are not prevalent today in this diabetic ulcer population,
indicating that CA-MRSA is likely to be the pathogen of concern.55,56 Compared to the
research on acute supportive wounds, research on chronic wounds has yet to distinguish
MRSA isolates as to more specific microbiological features. However, a common theme is
that effective control of the spread of MRSA in the diabetic ulcer population comes from
knowledge of the likely pathogens in one’s wound practice, including antibiotic sensitivity
profiles, when systemic antibiotics are required.65,67
Adequate off-loading, wound debridement, optimum blood flow, and appropriate sys-
temic antibiotics are the standard care for an infected diabetic ulcer, or one which has a
heavy bacterial burden, no matter what the organism.67
There is very little data on the role or the type of topical antimicrobial agents to be
used in an MRSA diabetic ulcer infection. Silver products in the form of foams, algi-
nates, and controlled release dressings are quite popular.69 No other topical agent has been
demonstrated to be effective in this patient population. However, the overall role of silver
in controlling the increasing MRSA reservoir has not been addressed.
The only other chronic wound, which has been discussed in the literature, relative to
thistopicisthechronicvenousstasisulcer.56 Silverproductsaretypicallythetopicalagents
most commonly discussed in the literature.70–74
It appears that MRSA colonization and infection are clearly increasing in the chronic
wound population. The distinction between CA-MRSA and HA-MRSA is not clearly de-
fined especially compared to the acute soft tissue wound. However, most data suggest that
CA-MRSA is the predominate isolate. The presence of MRSA places the patient at risk for
other more severe MRSA-related complications. In addition, at least for the diabetic ulcer,
there appears to be a greater risk of colonization evolving to infection.56,58
The basic treatment approach to the increased bacterial bioburden or infected chronic
wound is active debridement and systemic antibiotics. The role of topical antimicrobial
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agents in managing the growing problem of MRSA and the chronic wound remains
poorly defined. At present, silver-based agents and dressings remain the most popular
approach.
SUMMARY
MRSA is now a major cause of wound infections and bacteremias worldwide, and this
problem is growing at an epidemic pace.
Therearecurrently2typesofMRSA.Thereisthewell-establishedhospitalorhospital-
acquiredHA-MRSA,seenonthecompromisedpatientpopulationonantibiotics,especially
with an intravascular device in place. More recently CA- MRSA has been established,
typically seen in the young healthy, nonhospitalized population.
The multiantibiotic resistant HA-MRSA, typically transmitted by hand-to-skin con-
tact, is an increasing cause of bacteremia worldwide. The relatively antibiotic sensitive
CA- MRSA, also transferred by skin-to-skin contact, is an increasing cause of soft tissue
infection. Both are common causes of wound colonization and bacterial burden.
TheworldwideresistanceofbothtypesofMRSAreservoirsisincreasinginbothactive
infectionsandasymptomaticcarrierstates.Thecarrierstatescanbeverydangerousleading
to both bacteremias and other nosocomial infections in the carrier.
The impact of MRSA in acute and chronic soft-tissue wounds is described.
CA-MRSA is rapidly becoming the most common cause of acute soft-tissue wound
infections. The carrier state of CA-MRSA is also rapidly expanding, increasing the risk
of infections even in relatively minor wounds. The CDC’s recent guidelines have reported
that CA-MRSA must be considered to be the cause of any acute soft tissue infection and
appropriate systemic antibiotic choices must be made.
Inaddition,rigorousisolationandbarrierapproaches,aswellaspatient-careeducation,
need to be initiated to avoid further cross-contamination. Interestingly, there is really no
guidelines described as to the appropriate approach to topical antibiotic therapy, although
silver products are known to be effective against all variants of MRSA.
As to the chronic wound population, there is a clear increase in colonization, bac-
terial burden, and infection caused by MRSA, best documented in the diabetic ulcer
population. Of importance is the fact that the chronic wound population with MRSA
is at increased risk for both wound infections and systemic infections, especially bac-
teremias, if another acute illness occurs requiring hospitalization. These data reflect the
dangers of MRSA in the chronic wound as a focus for more life-threatening nosocomial
infections.
The distinction between CA-MRSA and HA-MRSA is not as well described for the
chronic wound as for the acute wound. However, there does appear to be clear indication
that CA-MRSA predominates in the outpatient population.
As with the acute wound, there is little definitive data as to the appropriate approach
to topical therapy for the colonized or infected chronic wound. Silver release products are
most common since MRSA is sensitive to silver.
It would be logical that topical therapy would be an important component in the
management of all of the types of wounds described, to decrease the reservoirs of both
types of MRSA.
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